PSA peptides for prostate cancer immunotherapy

OverviewProstate Specific Antigen (PSA) is a protein produced solely by prostate tissue, including tumors, and is considered a promising target for development of a prostate cancer vaccine. In fact, other groups are currently developing candidate…

Overview

Prostate-Specific Antigen (PSA) is a protein
produced solely by prostate tissue, including tumors, and is considered a
a promising target for the development of a prostate cancer vaccine. In fact,
other groups are currently developing candidate vaccines focused on
Class I-restricted CD8+ T-cell immunity, but the ultimate success of
those efforts are uncertain. UMB researchers have identified a set of
Class II-restricted, naturally processed, strongly immunogenic peptides
derived from PSA that promise an effective vaccine to prevent and treat
prostate cancer. The inventors showed that patients with a chronic
an inflammatory prostate condition called granulomatous prostatitis had in
common a particular immune cell glycoprotein is known as HLA-DRB1*1501, and
provided evidence that this is an autoimmune disease. Based on their
the hypothesis that successful immunotherapy for cancer will resemble
conditions of autoimmunity, the inventors performed studies in mice
transgenic for HLA-DRB1*1501 to identify particular PSA peptides that
are immunogenic. Two such 20-mer peptides were identified, each causing a
robust immune response when mice were challenged with the peptide or
the whole protein.

Applications

According to the Prostate Cancer Foundation,
prostate cancer is the most common non-skin cancer in America. One in
six American men will be diagnosed with prostate cancer, and 27,000
deaths resulted from the disease last year. While there are treatments
available, each is associated with risks and side effects. There remains
a critical need for new treatments for this common disease.

Advantages

-Stronger and more defined immune responses
through use of peptide versus whole protein. -Class II-restricted
peptides elicit CD4+ T cell response to augment and maintain CD8+ T cell
response, enlisting the full arsenal of the immune system against the
tumor. -Availability of useful monitoring options, such as
immunofluorescence staining with peptide/HLA complexes. -Potential use
as therapy for benign prostatic hypertrophy.

Stage of Development

Further pre-clinical studies will be conducted and clinical studies are required for developing a human vaccine.

R&D Required

see the State of Development

Website

https://www.umventures.org/technologies/psa-peptides-prostate-cancer-immunotherapy

Contact Info

University of Maryland Baltimore

Office of Technology Transfer
620 W Lexington St., 4th Floor
Baltimore, MD 21201
Email: ott@umaryland.edu
Phone: (410) 706-2380

Website: www.umventures.org